Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Index funds carry risks for retirees, including sequence of returns and drawdown volatility. Learn strategies to mitigate these concerns.
22,186 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Elle King's autism diagnosis reshaped her approach to life and money. This article translates that insight into perso...
As AI spending shifts from hype to heavy borrowing, Goldman Sachs warns AI's debt tsunami may tighten credit markets....
As Netflix stumbles, investors wonder if Disney down 2026 offers a rare contrarian opportunity. This article digs int...
The YieldMax NVDA Option Income Strategy ETF has drawn attention for its high advertised yield, but market dynamics a...
You don’t have to run every deal to build real estate wealth. This guide shows how to fire yourself still scale—deleg...
Public disputes can hit more than pride—they touch brand value and bank balances. Learn how chris brown avoids “inter...
Debt worries surround a proposed $1.5 trillion boost to the Pentagon budget, drawing pushback from fiscal hawks and r...
Anchorage Digital confirms it holds Strategy’s STRC perpetual preferred stock, marking a high-profile move by a regul...
A much-anticipated Las Vegas weekend fundraiser tied to Flavor Flav has people buzzing. But the real story isn’t the ...
A strong pharma dividend stock could be a powerful component of a retirement plan. Learn how to choose, invest, and c...
AI disruption is rattling markets, but Bitcoin still has unique safeguards. This guide explains why bitcoin safe from...